|
Zuma-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL). |
|
|
Consulting or Advisory Role - Cellular Biomedicine Group; Kite, a Gilead company |
Patents, Royalties, Other Intellectual Property - Moffitt (Inst) |
|
|
Consulting or Advisory Role - Celgene; Genentech/Abbvie; Kite, a Gilead company; Novartis; ProNAi; Spectrum Pharmaceuticals |
Research Funding - Celgene; Genentech; Janssen; Karyopharm Therapeutics; ProNAi |
|
|
Consulting or Advisory Role - Adaptive Biotechnologies; Genentech; Kite, a Gilead company; Pharmacyclics; Sanofi; Velos |
Research Funding - Pharmacyclics |
Patents, Royalties, Other Intellectual Property - Pharmacyclics |
Travel, Accommodations, Expenses - Pharmacyclics; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Kite, a Gilead company; Pharmacyclics |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Kite, a Gilead company |
|
|
No Relationships to Disclose |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Kite, a Gilead company |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Amgen; Kite, a Gilead company |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Kite, a Gilead company |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Kite, a Gilead company |
|
|
Employment - Kite, a Gilead company |
Leadership - Kite, a Gilead company |
Stock and Other Ownership Interests - Kite, a Gilead company |
|
|
Employment - Kite, a Gilead company |
Stock and Other Ownership Interests - Kite, a Gilead company |